BNR — Burning Rock Biotech Share News
0.000.00%
Last trade - 00:00- $164.08m
- $102.06m
- CNY539.57m
Burning Rock Biotech slips on downbeat Q1 revenue, bigger net loss
Burning Rock Biotech Ltd reports results for the quarter ended in March - Earnings Summary
Brief: Burning Rock Reports First Quarter 2021 Financial Results
Burning Rock Biotech Ltd expected to post a loss of CNY1.50 a share - Earnings Preview
Brief: Burning Rock Launches Prospective Pan-Cancer Multi-Omics Early Detection Study
Development Of Companion Diagnostics For ABSK091
Brief: Burning Rock's Liquid Biopsy Assay Achieved Strong Performance In The FDA-Led Seqc2 Study, With Results Published On Nature Biotechnology
Brief: Oncocyte And Burning Rock Execute Strategic Agreement To Distribute Determarx In China
OncoCyte: Rises on agreement to bring cancer test to China
Brief: Burning Rock Announces An Exclusive In-Licensing Of Cancer Test
Burning Rock Biotech: Falls on $58 mln discounted secondary offering
Brief: Burning Rock Announces Pricing of Upsized Registered Secondary Public Offering of American Depositary Shares
Brief: Burning Rock Biotech Ltd Says Shareholders Are Selling 1.8 Million American Depositary Shares
Brief: Burning Rock Reports Third Quarter 2020 Financial Results
Brief: Burning Rock Announces In-Licensing Of Myriad Mychoice® Tumor Testing In China
Brief: Burning Rock Announces Preliminary Results
Development Of Companion Diagnostics For Pralsetinib In China
NASDAQ RESUMED AT 11:34 AM
Brief: Burning Rock Biotech ADS Open At $22.80 In Debut On The Nasdaq Versus IPO Price Of $16.50 Per ADS